Oncology Department of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Fam Cancer. 2012 Sep;11(3):381-5. doi: 10.1007/s10689-012-9523-9.
Deleterious mutations in the RAD51C gene, which encodes a DNA double-strand break repair protein, have been reported to confer high-penetrance susceptibility to both breast and ovarian cancer. To confirm this we conducted a mutation screen of the RAD51C gene in 192 probands from high-risk breast and/or ovarian cancer families that do not carry BRCA1 or BRCA2 mutations. The nine exons of the RAD51C gene containing protein coding sequence were screened for mutations in genomic DNA from family probands by high-resolution melting analysis and direct DNA sequencing. Four missense variants, p.Ser364Gly, p.Ala126Thr, p.Val169Ala, and p.Thr287Ala were detected in six patients. The p.Ser364Gly variant is a novel variant predicted to have little influence on RAD51C activity. The p.Ala126Thr and p.Val169Ala variants have been reported to have no association with risk of breast cancer in a case-control study. However, p.Thr287Ala disrupts the DNA repair activity of RAD51C, suggesting some influence on risk. Consistent with published results from similar follow-up studies, we suggest that RAD51C mutations are rare events among high-risk breast cancer and breast/ovarian cancer families. Large population-based studies will be needed to reliably assess the prevalence and penetrance of inactivating mutations in the RAD51C susceptibility gene.
RAD51C 基因中的有害突变,该基因编码一种 DNA 双链断裂修复蛋白,已被报道赋予乳腺癌和卵巢癌的高外显率易感性。为了证实这一点,我们对 192 名来自高风险乳腺癌和/或卵巢癌家族且不携带 BRCA1 或 BRCA2 突变的先证者进行了 RAD51C 基因突变筛查。RAD51C 基因的九个外显子包含蛋白编码序列,我们通过高分辨率熔解分析和直接 DNA 测序对来自家族先证者的基因组 DNA 进行突变筛选。在六位患者中检测到四个错义变体,p.Ser364Gly、p.Ala126Thr、p.Val169Ala 和 p.Thr287Ala。p.Ser364Gly 变体是一种新的变体,预计对 RAD51C 活性影响不大。p.Ala126Thr 和 p.Val169Ala 变体在病例对照研究中与乳腺癌风险无关联。然而,p.Thr287Ala 破坏了 RAD51C 的 DNA 修复活性,表明对风险有一定影响。与类似随访研究的已发表结果一致,我们认为 RAD51C 突变在高风险乳腺癌和乳腺癌/卵巢癌家族中是罕见事件。需要进行大规模的基于人群的研究,以可靠评估 RAD51C 易感性基因中失活突变的流行率和外显率。